JP2017512838A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512838A5
JP2017512838A5 JP2017502946A JP2017502946A JP2017512838A5 JP 2017512838 A5 JP2017512838 A5 JP 2017512838A5 JP 2017502946 A JP2017502946 A JP 2017502946A JP 2017502946 A JP2017502946 A JP 2017502946A JP 2017512838 A5 JP2017512838 A5 JP 2017512838A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
seq
antibody
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017502946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512838A (ja
JP6598844B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023108 external-priority patent/WO2015148984A2/en
Publication of JP2017512838A publication Critical patent/JP2017512838A/ja
Publication of JP2017512838A5 publication Critical patent/JP2017512838A5/ja
Application granted granted Critical
Publication of JP6598844B2 publication Critical patent/JP6598844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017502946A 2014-03-27 2015-03-27 ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体 Active JP6598844B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2014074199 2014-03-27
CNPCT/CN2014/074199 2014-03-27
CNPCT/CN2014/081797 2014-07-08
CN2014081797 2014-07-08
PCT/US2015/023108 WO2015148984A2 (en) 2014-03-27 2015-03-27 Antibodies that bind human cannabinoid 1 (cb1) receptor

Publications (3)

Publication Number Publication Date
JP2017512838A JP2017512838A (ja) 2017-05-25
JP2017512838A5 true JP2017512838A5 (enExample) 2018-05-17
JP6598844B2 JP6598844B2 (ja) 2019-10-30

Family

ID=53008849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502946A Active JP6598844B2 (ja) 2014-03-27 2015-03-27 ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体

Country Status (16)

Country Link
US (4) US10308712B2 (enExample)
EP (2) EP4159761A1 (enExample)
JP (1) JP6598844B2 (enExample)
KR (2) KR102731863B1 (enExample)
CN (1) CN106232626B (enExample)
AU (1) AU2015237275B2 (enExample)
CA (1) CA2944049A1 (enExample)
CL (3) CL2016002433A1 (enExample)
ES (1) ES2915101T3 (enExample)
IL (1) IL248006B2 (enExample)
MA (1) MA39708A (enExample)
MX (1) MX2016012403A (enExample)
PE (1) PE20170258A1 (enExample)
RU (1) RU2730674C2 (enExample)
TW (1) TWI694086B (enExample)
WO (1) WO2015148984A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102731863B1 (ko) * 2014-03-27 2024-11-19 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
CA3000167A1 (en) * 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
US10995149B2 (en) 2017-06-05 2021-05-04 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use
EP3653713A4 (en) * 2017-07-13 2021-03-31 Kyowa Kirin Co., Ltd. ANTIBODY ANTIBODY AND PROCESS FOR STABILIZING BRIL FUSION PROTEIN INVOLVING THE ANTIBODY
CN108588071A (zh) * 2018-04-25 2018-09-28 和元生物技术（上海）股份有限公司 CRISPR-Cas9靶向敲除人肠癌细胞CNR1基因及其特异性的sgRNA
JP7431750B2 (ja) 2018-04-30 2024-02-15 武田薬品工業株式会社 カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用
US20210267959A1 (en) * 2018-07-17 2021-09-02 The Regents Of The University Of California Methods of treating renal disease
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
AU2023249518A1 (en) * 2022-04-04 2024-10-17 Bird Rock Bio Sub, Inc. Prediction and treatment of fast progressing renal disease
EP4534672A1 (en) * 2022-06-03 2025-04-09 Shionogi & Co., Ltd Antibody that binds to cannabinoid type 1 receptors
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途
WO2024212999A1 (zh) * 2023-04-11 2024-10-17 微境生物医药科技(上海)有限公司 Cbl-b抑制剂
CN118027211A (zh) * 2024-04-11 2024-05-14 上海惠盾因泰生物科技有限公司 一种识别重组egf-crm197疫苗的单克隆抗体及其应用
TW202604950A (zh) 2024-07-23 2026-02-01 美商鳥岩生物瑟博公司 肥胖症之治療
WO2026143180A1 (en) 2024-12-26 2026-07-02 Skye Bioscience, Inc. Anti-cb1 antibody compositions and therapeutic conjugates thereof
CN120647762B (zh) * 2025-06-16 2026-01-23 首都医科大学附属北京友谊医院 一种抗β1-AR-ECII抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466579A (en) 1987-12-28 1995-11-14 Psychemedics Corporation Hair analysis method
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5817766A (en) 1995-04-05 1998-10-06 Roche Diagnostic Systems, Inc. Reagents for a cannabinoid immunoassay
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US7754188B2 (en) * 2003-06-30 2010-07-13 Merck Sharp & Dohme Corp. Radiolabeled cannabinoid-1 receptor modulators
US20050095674A1 (en) 2003-07-23 2005-05-05 Lewis Deborah L. Cannabinoid receptor interacting proteins and methods of use
WO2005023232A2 (en) 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
WO2006129193A2 (en) 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8460362B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
WO2008048648A2 (en) * 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Cb1-modulating compounds and their use
HRP20120240T1 (hr) * 2007-05-23 2012-04-30 Merck Sharp & Dohme Corp. Piridil piperidin antagonisti receptora za oreksin
CN102089430B (zh) 2008-05-09 2015-02-04 Abbvie公司 针对渐进性糖化终极产物受体(rage)的抗体及其用途
FI20085579A0 (fi) 2008-06-12 2008-06-12 Valtion Teknillinen Kannabiskäytön toteaminen
IT1394400B1 (it) * 2009-02-25 2012-06-15 Neuroscienze Pharmaness S C Ar L Composizioni farmaceutiche
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
WO2012007847A2 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US9441033B2 (en) 2011-02-14 2016-09-13 Randox Laboratories Limited Detection of synthetic cannabinoids
US9435817B2 (en) 2011-02-14 2016-09-06 Randox Laboratories Limited Detection of synthetic cannabinoids
GB201102544D0 (en) 2011-02-14 2011-03-30 Randox Lab Ltd Assay
CN106983754A (zh) 2011-05-20 2017-07-28 国家医疗保健研究所 Cb1受体拮抗剂
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
EP2698383B1 (en) 2012-08-14 2020-11-25 Randox Laboratories Ltd. Detection of synthetic Cannabinoids
CA2915386A1 (en) * 2013-06-26 2014-12-31 Amgen Inc. Cb1 receptor antigen-binding proteins and uses thereof
KR20160097336A (ko) 2013-12-12 2016-08-17 스템센트알엑스 인코포레이티드 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
KR102731863B1 (ko) * 2014-03-27 2024-11-19 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체

Similar Documents

Publication Publication Date Title
RU2016141919A (ru) Антитела, связывающиеся с человеческим каннабиноидным рецептором 1 (св1)
JP6681433B2 (ja) Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
JP7273110B2 (ja) 高親和性抗ｖｅｇｆ抗体
AU2018312222B2 (en) Anti-CD47 antibodies and uses thereof
TWI564305B (zh) 治療性抗體
JP2018503380A5 (enExample)
JP2020501531A5 (enExample)
JP2017526370A5 (enExample)
JP2012501669A5 (enExample)
JP2022507679A (ja) Ｈｅｒ２／ｐｄ１二重特異性抗体
JP2008516970A5 (enExample)
JP2012531922A5 (ja) Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位
JP2012501670A5 (enExample)
JP2014500009A5 (enExample)
JP2013502913A5 (enExample)
JP2015530971A5 (enExample)
JP2010526028A5 (enExample)
JP2011207882A5 (enExample)
JP2015533853A5 (enExample)
JP2017505622A5 (enExample)
JP2013538057A5 (enExample)
AU2015253915A1 (en) Antibody binding to FcRn for treating autoimmune diseases
US20240101675A1 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
WO2021008523A1 (zh) 抗tigit抗体及其应用
JP2015509960A5 (enExample)